Schizophrenia Research
Volume 81, Issue 1 , Pages 47-63 , 1 January 2006

Apoptotic mechanisms and the synaptic pathology of schizophrenia

  • Leisa A. Glantz

      Affiliations

    • Department of Psychiatry, University of North Carolina—Chapel Hill, CB# 7160, Chapel Hill, NC 27599-7160, U.S.A.
    • ,
  • John H. Gilmore

      Affiliations

    • Department of Psychiatry, University of North Carolina—Chapel Hill, CB# 7160, Chapel Hill, NC 27599-7160, U.S.A.
    • ,
  • Jeffrey A. Lieberman

      Affiliations

    • Department of Psychiatry, Columbia University, New York, NY 10032, U.S.A.
    • ,
  • L. Fredrik Jarskog

      Affiliations

    • Department of Psychiatry, University of North Carolina—Chapel Hill, CB# 7160, Chapel Hill, NC 27599-7160, U.S.A.
    • Corresponding Author InformationCorresponding author. Tel.: +1 919 966 8035; fax: +1 919 966 8994.

Received 11 February 2005 ,Revised 12 August 2005 ,Accepted 15 August 2005.

References 

  1. Adamec E, Vonsattel JP, Nixon RA. DNA strand breaks in Alzheimer's disease. Brain Res. 1999;849:67–77
  2. Akbarian S, Bunney WE, Potkin SG, Wigal SB, Hagman JO, Sandman CA, et al. Altered distribution of nicotinamide–adenine dinucleotide phosphate–diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch. Gen. Psychiatry. 1993;50:169–177
  3. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney WE, Jones EG. Distorted distribution of nicotinamide–adenine dinucleotide phosphate–diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch. Gen. Psychiatry. 1993;50:178–187
  4. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry. 1995;52:258–266
  5. Akbarian S, Smith MA, Jones EG. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Brain Res. 1995;699:297–304
  6. Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE, Jones EG. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch. Gen. Psychiatry. 1996;53:425–436
  7. Allsopp TE, Kiselev S, Wyatt S, Davies AM. Role of Bcl-2 in the brain-derived neurotrophic factor survival response. Eur. J. Neurosci. 1995;7:1266–1272
  8. Anderson SA, Volk DW, Lewis DA. Increased density of microtubule associated protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic subjects. Schizophr. Res. 1996;19:111–119
  9. Andreasen NC. Schizophrenia: the fundamental questions. Brain Res. Brain Res. Rev. 2000;31:106–112
  10. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 1997;349:1730–1734
  11. Anegawa NJ, Guttmann RP, Grant ER, Anand R, Lindstrom J, Lynch DR. N-Methyl-d-aspartate receptor mediated toxicity in nonneuronal cell lines: characterization using fluorescent measures of cell viability and reactive oxygen species production. Brain Res. Mol. Brain Res. 2000;77:163–175
  12. Araghi-Niknam M, Fatemi SH. Levels of Bcl-2 and P53 are altered in superior frontal and cerebellar cortices of autistic subjects. Cell. Mol. Neurobiol. 2003;23:945–952
  13. Arnold SE, Hyman BT, Van Hoesen GW, Damasio AR. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch. Gen. Psychiatry. 1991;48:625–632
  14. Bai O, Wei Z, Lu W, Bowen R, Keegan D, Li XM. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 2002;69:278–283
  15. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res. 2004;1010:81–86
  16. Benes FM. The role of apoptosis in neuronal pathology in schizophrenia and bipolar disorder. Curr. Opin. Psychiatry. 2004;17:189–190
  17. Benes FM, Davidson J, Bird ED. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch. Gen. Psychiatry. 1986;43:31–35
  18. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry. 1991;48:996–1001
  19. Benes FM, Vincent SL, Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol. Psychiatry. 2001;50:395–406
  20. Benes FM, Walsh J, Bhattacharyya S, Sheth A, Berretta S. DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch. Gen. Psychiatry. 2003;60:359–364
  21. Benn SC, Woolf CJ. Adult neuron survival strategies — slamming on the brakes. Nat. Rev. Neurosci. 2004;5:686–700
  22. Berger GE, Wood S, McGorry PD. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacol. Bull. 2003;37:79–101
  23. Bernstein M, Lichtman JW. Axonal atrophy: the retraction reaction. Curr. Opin. Neurobiol. 1999;9:364–370
  24. Bredesen DE. Neural apoptosis. Ann. Neurol. 1995;38:839–851
  25. Burek MJ, Oppenheim RW. Programmed cell death in the developing nervous system. Brain Pathol. 1996;6:427–446
  26. Cahn W, Pol HE, Lems EB, Van Haren NE, Schnack HG, van der Linden JA, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch. Gen. Psychiatry. 2002;59:1002–1010
  27. Camandola S, Mattson MP. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression. J. Neurosci. Res. 2000;61:134–139
  28. Campbell DS, Holt CE. Apoptotic pathway and MAPKs differentially regulate chemotropic responses of retinal growth cones. Neuron. 2003;37:939–952
  29. Cecil KM, Lenkinski RE, Gur RE, Gur RC. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology. 1999;20:131–140
  30. Chen DF, Schneider GE, Martinou JC, Tonegawa S. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature. 1997;385:434–439
  31. Cheng A, Wang S, Cai J, Rao MS, Mattson MP. Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain. Dev. Biol. 2003;258:319–333
  32. Clark RSB, Chen M, Kochanek PM, Watkins SC, Jin KL, Draviam R, et al. Detection of single- and double-strand DNA breaks after traumatic brain injury in rats: comparison of in situ labeling techniques using DNA polymerase I, the Klenow fragment of DNA polymerase I, and terminal deoxynucleotidyl transferase. J. Neurotrauma. 2001;18:675–689
  33. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb. Cortex. 2002;12:386–394
  34. Coulton GR, Rogers B, Strutt P, Skynner MJ, Watt DJ. In situ localisation of single-stranded DNA breaks in nuclei of a subpopulation of cells within regenerating skeletal muscle of the dystrophic mdx mouse. J. Cell Sci. 1992;102(Pt 3):653–662
  35. Dash PK, Blum S, Moore AN. Caspase activity plays an essential role in long-term memory. NeuroReport. 2000;11:2811–2816
  36. Deutch AY. The effects of dopamine denervation on prefrontal cortical structure and reversal by atypical antipsychotic drugs. Biol. Psychiatry. 2005;57:82S
  37. Deutch AY, Jing D. Prefrontal cortical dopamine denervation decreases dendritic spine density in pyramidal neurons. Schizophr. Res. 2003;60:56
  38. Dooley AE, Pappas IS, Parnavelas JG. Serotonin promotes the survival of cortical glutamatergic neurons in vitro. Exp. Neurol. 1997;148:205–214
  39. Faber KM, Haring JH. Synaptogenesis in the postnatal rat fascia dentata is influenced by 5-HT1a receptor activation. Brain Res. Dev. Brain Res. 1999;114:245–252
  40. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?. J. Psychiatr. Res. 1982;17:319–334
  41. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 2003;348:1365–1375
  42. Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, D'Emilia DM, et al. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J. Neurosci. 2002;22:4015–4024
  43. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM, et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry. 1998;65:446–453
  44. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992;119:493–501
  45. German TT, Tong RI, Gilmore JH, Lieberman JA, Jarskog LF. Regulation of apoptosis by typical and atypical antipsychotics in rat frontal cortex. Biol. Psychiatry. 2004;55:214S
  46. Gilman CP, Mattson MP. Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility?. Neuromolecular Med. 2002;2:197–214
  47. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch. Gen. Psychiatry. 1997;54:943–952
  48. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry. 2000;57:65–73
  49. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. DNA fragmentation in the temporal cortex of subjects with schizophrenia. Biol. Psychiatry. 2003;53:185S–186S
  50. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 2001;158:1367–1377
  51. Guo ZH, Mattson MP. Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb. Cortex. 2000;10:50–57
  52. Gylys KH, Fein JA, Cole GM. Caspase inhibition protects nerve terminals from in vitro degradation. Neurochem. Res. 2002;27:465–472
  53. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122(Pt 4):593–624
  54. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 2005;25:372–383
  55. Hof PR, Haroutunian V, Friedrich VL, Byne W, Buitron C, Perl DP, et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry. 2003;53:1075–1085
  56. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998;30:193–208
  57. Hulshoff Pol HE, Schnack HG, Bertens MG, Van Haren NE, van d.T. I. , Staal WG, et al. Volume changes in gray matter in patients with schizophrenia. Am. J. Psychiatry. 2002;159:244–250
  58. Huttenlocher PR. Synaptic density in human frontal cortex — developmental changes and effects of aging. Brain Res. 1979;163:195–205
  59. Huttenlocher PR, Dabholkar AS. Regional differences in synaptogenesis in human cerebral cortex. J. Comp. Neurol. 1997;387:167–178
  60. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283:70–74
  61. Iseki S. DNA strand breaks in rat tissues as detected by in situ nick translation. Exp. Cell Res. 1986;167:311–326
  62. Ivins KJ, Bui ET, Cotman CW. Beta-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol. Dis. 1998;5:365–378
  63. Jacobs B, Driscoll L, Schall M. Life-span dendritic and spine changes in areas 10 and 18 of human cortex: a quantitative Golgi study. J. Comp. Neurol. 1997;386:661–680
  64. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J. Neural Transm. 1986;65:303–326
  65. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol. Psychiatry. 2000;48:641–650
  66. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am. J. Psychiatry. 2004;161:109–115
  67. Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 2005;29:846–858
  68. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 1991;148:1301–1308
  69. Jin K, Chen J, Nagayama T, Chen M, Sinclair J, Graham SH, et al. In situ detection of neuronal DNA strand breaks using the Klenow fragment of DNA polymerase I reveals different mechanisms of neuron death after global cerebral ischemia. J. Neurochem. 1999;72:1204–1214
  70. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley neuropathology consortium. Mol. Psychiatry. 2000;5:142–149
  71. Kanold PO, Kara P, Reid RC, Shatz CJ. Role of subplate neurons in functional maturation of visual cortical columns. Science. 2003;301:521–525
  72. Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Lee CU, Ciszewski AA, et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am. J. Psychiatry. 2003;160:156–164
  73. Kayalar C, Ord T, Testa MP, Zhong LT, Bredesen DE. Cleavage of actin by interleukin 1 beta-converting enzyme to reverse DNase I inhibition. Proc. Natl. Acad. Sci. U. S. A. 1996;93:2234–2238
  74. Keane RW, Kraydieh S, Lotocki G, Alonso OF, Aldana P, Dietrich WD. Apoptotic and antiapoptotic mechanisms after traumatic brain injury. J. Cereb. Blood Flow Metab. 2001;21:1189–1198
  75. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res. 1998;780:260–269
  76. Kruman I, Guo Q, Mattson MP. Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J. Neurosci. Res. 1998;51:293–308
  77. Kung L, Roberts RC. Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study. Synapse. 1999;31:67–75
  78. Lawrence MS, Ho DY, Sun GH, Steinberg GK, Sapolsky RM. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. J. Neurosci. 1996;16:486–496
  79. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28:325–334
  80. Lewis DA, Cruz DA, Melchitzky DS, Pierri JN. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. Am. J. Psychiatry. 2001;158:1411–1422
  81. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000;288:335–339
  82. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry. 1999;46:729–739
  83. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry. 2001;50:884–897
  84. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry. 2005;62:361–370
  85. Lotocki G, Keane RW. Inhibitors of apoptosis proteins in injury and disease. IUBMB Life. 2002;54:231–240
  86. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 2001;25:463–493
  87. Margolis RL, Chuang DM, Post RM. Programmed cell death: implications for neuropsychiatric disorders. Biol. Psychiatry. 1994;35:946–956
  88. Martin SJ, O'Brien GA, Nishioka WK, McGahon AJ, Mahboubi A, Saido TC, et al. Proteolysis of fodrin (non-erythroid spectrin) during apoptosis. J. Biol. Chem. 1995;270:6425–6428
  89. Masliah E, Mallory M, Alford M, Tanaka S, Hansen LA. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1998;57:1041–1052
  90. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry. 2001;58:148–157
  91. Mattson MP, Duan W. “Apoptotic” biochemical cascades in synaptic compartments: roles in adaptive plasticity and neurodegenerative disorders. J. Neurosci. Res. 1999;58:152–166
  92. Mattson MP, Keller JN, Begley JG. Evidence for synaptic apoptosis. Exp. Neurol. 1998;153:35–48
  93. Mattson MP, Duan W, Pedersen WA, Culmsee C. Neurodegenerative disorders and ischemic brain diseases. Apoptosis. 2001;6:69–81
  94. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2004;27:589–594
  95. Maurer I, Zierz S, Moller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 2001;48:125–136
  96. McAllister AK. Neurotrophins and neuronal differentiation in the central nervous system. Cell. Mol. Life Sci. 2001;58:1054–1060
  97. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res. Brain Res. Rev. 2000;31:288–294
  98. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 2002;22:2718–2729
  99. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28:53–67
  100. Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Mol. Interv. 2003;3:27–39
  101. Morrison RS, Kinoshita Y, Johnson MD, Guo W, Garden GA. p53-dependent cell death signaling in neurons. Neurochem. Res. 2003;28:15–27
  102. Mukerjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr. Res. 1996;19:19–26
  103. Nieoullon A, Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr. Opin. Neurol. 2003;16(Suppl 2):S3–S9
  104. Oh YJ, Swarzenski BC, O'Malley KL. Overexpression of Bcl-2 in a murine dopaminergic neuronal cell line leads to neurite outgrowth. Neurosci. Lett. 1996;202:161–164
  105. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 1995;52:998–1007
  106. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell. 1993;74:609–619
  107. Oppenheim RW. Cell death during development of the nervous system. Annu. Rev. Neurosci. 1991;14:453–501
  108. Pakkenberg B. Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical dissectors. Biol. Psychiatry. 1993;34:768–772
  109. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361:281–288
  110. Paradis E, Douillard H, Koutroumanis M, Goodyer C, LeBlanc A. Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J. Neurosci. 1996;16:7533–7539
  111. Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1996;93:14182–14187
  112. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 1991;48:563–568
  113. Pettegrew JW, Keshavan MS, Minshew NJ. 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. Schizophr. Bull. 1993;19:35–53
  114. Pierri JN, Volk CL, Auh S, Sampson A, Lewis DA. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch. Gen. Psychiatry. 2001;58:466–473
  115. Pompl PN, Yemul S, Xiang Z, Ho L, Haroutunian V, Purohit D, et al. Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease. Arch. Neurol. 2003;60:369–376
  116. Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur. J. Neurosci. 2003;17:1563–1570
  117. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry. 1998;55:215–224
  118. Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, Meltzer H, Overholser J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 2002;57:127–138
  119. Robertson RT, Annis CM, Baratta J, Haraldson S, Ingeman J, Kageyama GH, et al. Do subplate neurons comprise a transient population of cells in developing neocortex of rats?. J. Comp. Neurol. 2000;426:632–650
  120. Sastry PS, Rao KS. Apoptosis and the nervous system. J. Neurochem. 2000;74:1–20
  121. Satou T, Cummings BJ, Cotman CW. Immunoreactivity for Bcl-2 protein within neurons in the Alzheimer's disease brain increases with disease severity. Brain Res. 1995;697:35–43
  122. Sawa A, Oyama F, Cairns NJ, Amano N, Matsushita M. Aberrant expression of bcl-2 gene family in Down's syndrome brains. Brain Res. Mol. Brain Res. 1997;48:53–59
  123. Schlaepfer TE, Harris GJ, Tien AY, Peng LW, Lee S, Federman EB, et al. Decreased regional cortical gray matter volume in schizophrenia. Am. J. Psychiatry. 1994;151:842–848
  124. Segal M, Korkotian E, Murphy DD. Dendritic spine formation and pruning: common cellular mechanisms?. Trends Neurosci. 2000;23:198
  125. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry. 1999;45:17–25
  126. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry. 1995;52:805–818
  127. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J. Comp. Neurol. 1998;392:402–412
  128. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr. Res. 2001;49:1–52
  129. Sporn AL, Greenstein DK, Gogtay N, Jeffries NO, Lenane M, Gochman P, et al. Progressive brain volume loss during adolescence in childhood-onset schizophrenia. Am. J. Psychiatry. 2003;160:2181–2189
  130. Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Malla A, et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 1995;52:399–406
  131. Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am. J. Psychiatry. 2004;161:882–888
  132. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–1462
  133. Thompson PM, Vidal C, Giedd JN, Gochman P, Blumenthal J, Nicolson R, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001;98:11650–11655
  134. Thune JJ, Uylings HB, Pakkenberg B. No deficit in total number of neurons in the prefrontal cortex in schizophrenics. J. Psychiatr. Res. 2001;35:15–21
  135. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 2001;55:597–610
  136. Vekrellis K, McCarthy MJ, Watson A, Whitfield J, Rubin LL, Ham J. Bax promotes neuronal cell death and is downregulated during the development of the nervous system. Development. 1997;124:1239–1249
  137. Verma P, Chierzi S, Codd AM, Campbell DS, Meyer RL, Holt CE, et al. Axonal protein synthesis and degradation are necessary for efficient growth cone regeneration. J. Neurosci. 2005;25:331–342
  138. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience. 2001;107:535–550
  139. Wei Z, Mousseau DD, Richardson JS, Dyck LE, Li XM. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid (25–35) by modulating Bax and Bcl-X(l/s) expression and localization. J. Neurosci. Res. 2003;74:942–947
  140. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry. 2003;8:592–610
  141. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 1987;44:660–669
  142. Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?. Arch. Gen. Psychiatry. 2002;59:553–558
  143. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry. 1986;43:114–124
  144. Wible CG, Kubicki M, Yoo SS, Kacher DF, Salisbury DF, Anderson MC, et al. A functional magnetic resonance imaging study of auditory mismatch in schizophrenia. Am. J. Psychiatry. 2001;158:938–943
  145. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004;27:683–690
  146. Woo TU, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-d-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry. 2004;61:649–657
  147. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int. Rev. Cyt. 1980;68:251–306
  148. Yan XX, Najbauer J, Woo CC, Dashtipour K, Ribak CE, Leon M. Expression of active caspase-3 in mitotic and postmitotic cells of the rat forebrain. J. Comp. Neurol. 2001;433:4–22
  149. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000;407:802–809
  150. Zhang KZ, Westberg JA, Holtta E, Andersson LC. BCL2 regulates neural differentiation. Proc. Natl. Acad. Sci. U. S. A. 1996;93:4504–4508
  151. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. Arch. Gen. Psychiatry. 1992;49:195–205

PII: S0920-9964(05)00368-3

doi: 10.1016/j.schres.2005.08.014

Schizophrenia Research
Volume 81, Issue 1 , Pages 47-63 , 1 January 2006

Article Tools

* Image Usage & Resolution